Onco360 Chosen for Highly Select VENCLEXTA(TM) (VENETOCLAX) Pharmacy Network

Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been chosen to be part of the highly select pharmacy network for VENCLEXTA.

VENCLEXTA, an oral oncology medication made by AbbVie, Inc., has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a 17p deletion and have been treated with at least one prior therapy.1 According to the American Cancer Society, approximately 18,960 new cases of CLL are diagnosed in the United States each year.

“On behalf of the entire Onco360 organization, we are extremely proud to have been selected to be part of the limited distribution pharmacy network for this highly anticipated new medication,” said Onco360 President and CEO Paul Jardina. “At Onco360, our focus has always been on providing the most comprehensive and compassionate Oncology Pharmacy care possible for cancer patients. Our focus and patient-first approach continues to resonate with patients and their families as well as physicians, pharmaceutical companies and other participants across the continuum of care, and we are thrilled to add VENCLEXTA to our limited distribution portfolio of products.”

VENCLEXTA is immediately available for prescription order from Onco360.

For more information about VENCLEXTA please visit www.VENCLEXTA.com.

For more information about Onco360 please visit www.Onco360.com.

1. VENCLEXTA Prescribing Information; AbbVie, Inc., 2016.

About Onco360 Oncology Pharmacy:

Onco360 (http://onco360.com) is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The Company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 is headquartered in Louisville, KY and dispenses nationally through its network of URAC-, ACHC-, and JCAHO-accredited Oncology Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, made a significant strategic investment in Onco360 in December 2013.

Onco360® | 1901 Campus Place | Louisville, KY 40299

View source version on businesswire.com: http://www.businesswire.com/news/home/20160414005450/en/